Sandra Möhr

Mrs. Sandra Möhr

Urology, Rehab, Basel, Basel-Stadt, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
CACollene E Anderson
Collene E Anderson
JCJonviea D. Chamberlain
Jonviea D. Chamberlain
XJXavier Jordan
Xavier Jordan
Thomas M. KesslerThomas M. Kessler
Thomas M. Kessler
ELEugenia Luca
Eugenia Luca
TGthe SwiSCI Study Group
the SwiSCI Study Group

13 August 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
VBVeronika Birkhäuser
Veronika Birkhäuser
MLMartina D. Liechti
Martina D. Liechti
CACollene E Anderson
Collene E Anderson
LBLucas M Bachmann
Lucas M Bachmann
SBSarah Baumann
Sarah Baumann
Thomas M. KesslerThomas M. Kessler
Thomas M. Kessler
Introduction Neurogenic lower urinary tract dysfunction (NLUTD), including neurogenic detrusor overactivity (NDO) and detrusor sphincter dyssynergia, is one of the most frequent and devastating sequelae of spinal cord injury (SCI), as it can lead to urinary incontinence and secondary damage such as renal failure. Transcutaneous tibial nerve stimulation (TTNS) is a promising, non-invasive neuromodulatory intervention that may prevent the emergence of the C-fibre evoked bladder reflexes that are thought to cause NDO. This paper presents the protocol for TTNS in acute SCI (TASCI), which will evaluate the efficacy of TTNS in preventing NDO. Furthermore, TASCI will provide insight into the mechanisms underlying TTNS, and the course of NLUTD development after SCI. Methods and analysis TASCI is a nationwide, randomised, sham-controlled, double-blind clinical trial, conducted at all four SCI centres in Switzerland. The longitudinal design includes a baseline assessment period 5–39 days after acute SCI and follow-up assessments occurring 3, 6 and 12 months after SCI. A planned 114 participants will be randomised into verum or sham TTNS groups (1:1 ratio), stratified on study centre and lower extremity motor score. TTNS is performed for 30 min/day, 5 days/week, for 6–9 weeks starting within 40 days after SCI. The primary outcome is the occurrence of NDO jeopardising the upper urinary tract at 1 year after SCI, assessed by urodynamic investigation. Secondary outcome measures assess bladder and bowel function and symptoms, sexual function, neurological structure and function, functional independence, quality of life, as well as changes in biomarkers in the urine, blood, stool and bladder tissue. Safety of TTNS is the tertiary outcome. Ethics and dissemination TASCI is approved by the Swiss Ethics Committee for Northwest/Central Switzerland, the Swiss Ethics Committee Vaud and the Swiss Ethics Committee Zürich (#2019-00074). Findings will be disseminated through peer-reviewed publications. Trial registration number NCT03965299.

15 February 2022 in European Urology Open Science
Verified
Journal Article
Open access
CACollene E Anderson
Collene E Anderson
VBVeronika Birkhäuser
Veronika Birkhäuser
XJXavier Jordan
Xavier Jordan
MLMartina D. Liechti
Martina D. Liechti
ELEugenia Luca
Eugenia Luca
MBMartin WG Brinkhof
Martin WG Brinkhof
There is limited epidemiological evidence describing contemporary neuro-urological management of persons with acute spinal cord injury (SCI). To describe neurogenic lower urinary tract dysfunction (NLUTD) management at discharge from SCI rehabilitation. The population-based Swiss Spinal Cord Injury (SwiSCI) cohort study prospectively collected data from 602 adults undergoing specialized postacute SCI rehabilitation from 2013 to 2020. The management strategy was based on the European Association of Urology (EAU) Guidelines on Neuro-Urology. Data were collected at discharge using the International SCI Lower Urinary Tract Function Basic Data Set. Multivariable logistic regression adjusting for demographics, SCI characteristics, and center, with inverse probability weighting accounting for sampling bias, was used to produce prevalence estimates and identify predictors of lower urinary tract symptoms (LUTS) and NLUTD management outcomes. At discharge (median time after SCI: 5.0 mo [Q1-Q3: 3.0–7.2]), the prevalence of LUTS or managed NLUTD was 82% (95% confidence interval [CI]: 79–85%). SCI completeness was the main predictor of LUTS and managed NLUTD. The risk of urinary incontinence was elevated in females (odds ratio 1.98 [95% CI: 1.18–3.32]) and with complete lesions (odds ratio 4.71 [95% CI: 2.52–8.81]). Voiding dysfunction was most commonly managed with intermittent catheterization (prevalence 39% [95% CI: 35–42%]), followed by indwelling catheterization (prevalence 22% [95% CI: 18–25%]). The prevalence of antimuscarinic or mirabegron use was 29% (95% CI: 26–33%). Urodynamic and renal function data were not collected. Our population-based description of urological management in Swiss SCI centers utilizing the EAU Guidelines on Neuro-Urology may be used as a reference for evaluation in other settings. Data further indicate a need for sex-specific neuro-urological management research. At discharge from spinal cord injury (SCI) rehabilitation, a majority of patients have lower urinary tract problems, especially those with complete SCI. Women have a higher risk of urinary incontinence.

8 July 2020 in BMC Urology
Verified
Journal Article
Open access
PDF file
JPJürgen Pannek
Jürgen Pannek
KEKarel Everaert
Karel Everaert
SMSandra Möhr
Sandra Möhr
WVWill Vance
Will Vance
FAFrank Van der Aa
Frank Van der Aa
JKJürg Kesselring
Jürg Kesselring
Background: In patients with indwelling bladder catheters for > 2 weeks, bacterial colonization is inevitable, leading to urinary tract infections or encrustations with subsequent catheter blockage. Currently, bladder irrigations are the most frequently used prophylactic means, but the best solution remains yet to be determined. In vitro studies demonstrate that polihexanide is a promising option for catheter irrigation, but no data about safety and tolerability exist. Methods: In a prospective observational study in patients with indwelling bladder catheter for > 2 weeks, a 0.02% polihexanide solution was used to rinse the catheter on five consecutive days. Adverse events, tolerability and vital signs were assessed before, during, after and at the end of the treatment period. Results: There was no serious adverse event in the study. A total of 28 adverse events (AEs) in 15 (46.88%) participants were experienced. Absolute changes in pain scores were not clinically relevant. No incidences of either flushing or sweating were found during instillation. Bladder spasms during instillation were reported in two cases during a single instillation. Mean pulse rates did not change by more than 3 beats per minute. Mean changes in body temperature did not exceed 0.12 °C. Clinically relevant changes in blood pressure were recorded for 3 patients. Conclusions: This is the first study to demonstrate that a 0.02% polihexanide solution can safely be used for catheter irrigation. Trial registration: ClinicalTrials.gov (NCT02157415), June 6th, 2014.

12 October 2022 in Spinal Cord
Verified
Journal Article
Closed access
PDF file
CACollene E Anderson
Collene E Anderson
VBVeronika Birkhäuser
Veronika Birkhäuser
MLMartina D. Liechti
Martina D. Liechti
XJXavier Jordan
Xavier Jordan
ELEugenia Luca
Eugenia Luca
MBMartin WG Brinkhof
Martin WG Brinkhof

1 September 2020 in European Urology Focus
Verified
Journal Article
Closed access
MLMartina D. Liechti
Martina D. Liechti
SLStéphanie van der Lely
Stéphanie van der Lely
SSStephanie A Stalder
Stephanie A Stalder
CACollene E Anderson
Collene E Anderson
VBVeronika Birkhäuser
Veronika Birkhäuser
Thomas M. KesslerThomas M. Kessler
Thomas M. Kessler